N6-methyladenosine reader protein IGF2BP1 suppresses CD8?+?T cells-mediated tumor cytotoxicity and apoptosis in colon cancer

Tumor immune escape is an important manner for colon cancer to escape effective killing by immune system. Currently, the immune checkpoint PD-1/PD-L1-targeted immunotherapy has emerged as a promising therapeutic strategy in colon cancer. Here, present work aims to investigate the biological function of N 6 -methyladenosine (m 6 A) reader insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1) in regulating colon cancer’s immune escape and CD8?+?T cells-mediated tumor cytotoxicity and apoptosis. Results illustrated that IGF2BP1 was closely correlated to the colon cancer patients’ poor clinical outcome. Functionally, upregulation of IGF2BP1 suppressed the CD8 + T-cells mediated antitumor immunity through reducing their tumor cytotoxicity. Mechanistically, MeRIP-Seq revealed that programmed death ligand 1 (PD-L1) mRNA had a remarkable m 6 A modified site on 3’-UTR genomic. Moreover, PD-L1 acted as the target of IGF2BP1, which enhanced the stability of PD-L1 mRNA. Overall, these results indicated that IGF2BP1 targeted PD-L1 to accelerate the immune escape in colon cancer by reducing CD8?+?T cells-mediated tumor cytotoxicity in m 6 A-dependent manner. The findings demonstrate the potential of m 6 A-targeted immune checkpoint blockade in colon cancer, providing a novel insight for colon cancer immune escape and antitumor immunity in further precise treatment.

文章引用产品列表